Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Apple Restores Telegram to App Store After Content Policy Violation 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
NAPANEE, Ontario, March 16, 2018 -- ABcann Global Corporation (TSXV:ABCN) (Frankfurt:23Q) (OTC:ABCCF) ("ABcann" or the "Company") announced that Ken Clement, ABcann's founder and director, has resigned from the Board of Directors.
Paul Lucas, ABcann's Chair, commented, "On behalf of the Board, we thank Ken for his vision in starting the company and growing it from a start-up organization into a well-funded publicly-traded licensed producer with a bright future. We wish Ken well in his future endeavours."
About ABcann:
ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.
The Company is expanding its cultivation capacity and pursuing partnerships and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.
ON BEHALF OF THE BOARD OF DIRECTORS
"Barry Fishman"
Barry Fishman
CEO and Director
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Barry Fishman (CEO and Director) [email protected] Michael Bumby (CFO) [email protected]
